Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph G Zinner

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancerRalph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trialRalph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trialRitsuko Komaki, Jin Soo Lee, Luka Milas, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget|September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancerRalph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trialRalph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trialRitsuko Komaki, Jin Soo Lee, Luka Milas, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget|September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Pageof 5